Sentences with phrase «patent cliff»

With Merck facing a significant patent cliff in 2017, continued momentum in the new product cycle and a keen focus on cost controls will be key to offsetting generic erosion.

«In terms of life sciences today, with a lot of patent cliffs hitting simultaneously and generics growing faster than you can imagine, it's putting a lot of financial pressure on the largest companies.

Analysts have been pushing for Pfizer to make some sort of major deal to shore up its pipeline in the face of multiple major patent expirations, including impending patent cliffs for Viagra and Lyrica.

They have either fallen off the proverbial patent cliff (Novartis» Diovan, which lost US exclusivity in 2012) or succumbed to a stronger U.S. dollar against European and Asian currencies despite rising sales (Novo Nordisk's NovoLog, which also missed this year's list).

Pharmaceutical industry watchdogs have long looked to 2012 as the year of the steepest drop off the industry's so - called patent cliff, and so far this year companies have indeed lost a record number of patents on blockbuster drugs.

Revenue growth has slowed as many companies sink more resources into developing the next blockbuster drug; what's more, the «patent cliff» for the last round of megabillion - dollar drugs — when generics firms typically see a sales spurt — happened a few years ago.

Now, the innovation pipelines are dry, the pharma companies are peering (or falling) over the patent cliff.

Many said that Bristol, with its patent cliff looming, was cutting the strings of its parachute.

On top of this, many big pharma firms who have been coasting along with their big name drugs, are fast approaching a patent cliff, suggesting that some of their most popular drugs — and important revenue streams — are likely to disappear as they go generic in the coming years.

These two companies, Align Technologies (ALGN) and Regeneron Pharmaceuticals (REGN), both face looming patent cliffs.

Second, legitimate patents are risky because they might run out, and often do, before the FDA approves the prescription, essentially creating a patent cliff from the get - go.

However, that under - performance may end this year given that major patent expirations during the patent cliff, which peaked in 2012, have been digested, and expense - cutting programs have been put in place to boost profitability.

No. 3: The year of big pharma In the past five years, big cap pharmaceutical stocks have lagged biotech stocks because they've struggled to fill revenue gaps created by the patent cliff.

As the pharmaceutical industry's blockbuster drugs fall off the patent cliff, with precious few drugs in the pipeline to replace them, there are signs that big pharma could turn more of its attention to biologically derived medicines.

«The patent cliffs wouldn't be such a big issue if research and development productivity hadn't collapsed.»

But as its patent expires on November 30 and its first generic competitor takes the stage, Lipitor is also a painful reminder of the challenge that such «patent cliffs» pose for the big drug companies, including Lipitor's developer Pfizer, based in New York.

The drying drug pipeline and looming patent cliff, together with the ailing economy, has hit the drug discovery business hard, forcing the industry to lay off workers and rethink and restructure its research and development models.

Including Lipitor, patent expiries in 2010 - 13 will jeopardize revenues amounting to more than US$ 95 billion for ten of the largest drug companies (see «Peering over the patent cliff»).

Finally, a review of this year's Canadian biotech and pharma licensing trends shows that even facing a patent cliff, pharmas (as licensing payers) still wield a fair amount of bargaining power.